Revolution Medicines, Inc.

RVMDNASDAQ

Market cap40.98B USDAs of Sep 22, 2026

Healthcare· Biotechnology· US

$192.76

Session change unavailable

Market closed · NASDAQ

Status checked Oct 25, 2026, 12:37 AM · America/New_York

Observed Sep 21, 2026, 8:00 PM UTC · Last available price

Revolution Medicines, Inc. (RVMD)

Loading market observation…

Revolution Medicines, Inc. (RVMD) stock forecast and scoring

Review the dated model forecast and five-factor Scorecard for RVMD. Each has its own availability and reference date; a score is a relative comparison, not a price prediction.

12M forecast summary

Target date · Sep 21, 2027

Lower Estimate (P10)

$110.04

-42.9%

Median Estimate (P50)

$218.24

+13.2% from starting price

Upper Estimate (P90)

$385.65

+100.1%

Median Estimate: $218.24
Starting price: $192.76
Change from starting price: +13.2%
Target date: Sep 21, 2027
Data through: Sep 21, 2026

The estimate uses its dated starting price. It does not predict returns from today’s quote.

View forecast details, dates and available ranges

Stock scorecard

Loading research…

Company Overview

Revolution Medicines, Inc. is a precision oncology firm operating in the clinical development stage, dedicated to creating innovative treatments that target novel pathways crucial for RAS-driven cancers. Its pipeline includes several promising drug candidates: RMC-4630, an SHP2 inhibitor, is currently undergoing Phase 1/2 clinical trials for various solid tumors, such as gynecological and colorectal cancers. The company's portfolio also features RMC-5845, a selective inhibitor designed to target SOS1, a protein responsible for activating RAS within cells, and RMC-5552, a highly selective inhibitor for hyperactive mTORC1 signaling found in cancerous cells. Further expanding its therapeutic arsenal, Revolution Medicines is advancing RMC-6291, which selectively inhibits mutated forms of KRASG12C(ON) and NRASG12C(ON). Another promising compound, RMC-6236, specifically targets and inhibits a range of active RAS(ON) variants. Its research efforts also encompass other active RAS inhibitors aimed at KRASG13C(ON) and KRASG12D(ON) mutations. Revolution Medicines has established a collaborative partnership with Sanofi to research and develop SHP2 inhibitors, a collaboration that includes the development of RMC-4630. Established in 2014, Revolution Medicines, Inc. operates from its corporate headquarters situated in Redwood City, California.

Similar Stocks

Research snapshot

Loading research…

Revolution Medicines, Inc. research

Loading research…

Model estimates are informational, not investment advice. They are uncertain, may be wrong, and do not guarantee future prices.

Company Overview

Similar Stocks

Explore related companies in our coverage. Open a stock for its full forecast and Scorecard.

BridgeBio Pharma, Inc.

BBIO

Same industryBiotechnology

Latest observed price

$66.58

Observed
Sep 21, 2026

12-month forecast

Median (P50)

$77.33

+16.1%

From $66.58 starting price

Target Sep 21, 2027

Overall Score

Unavailable

Forecast basis Sep 21, 2026

Score date —

View stock

BioMarin Pharmaceutical Inc.

BMRN

Same industryBiotechnology

Latest observed price

$64.06

Observed
Sep 21, 2026

12-month forecast

Median (P50)

$68.31

+6.6%

From $64.06 starting price

Target Sep 21, 2027

Overall Score

Moderate

Forecast basis Sep 21, 2026

Score date Sep 22, 2026

View stock

Exelixis, Inc.

EXEL

Same industryBiotechnology

Latest observed price

$57.22

Observed
Sep 21, 2026

12-month forecast

Median (P50)

—

Overall Score

Strong

Forecast basis —

Score date Sep 22, 2026

View stock

Ionis Pharmaceuticals, Inc.

IONS

Same industryBiotechnology

Latest observed price

$44.90

Observed
Sep 21, 2026

12-month forecast

Median (P50)

$54.76

+22.0%

From $44.90 starting price

Target Sep 21, 2027

Overall Score

Very Weak

Forecast basis Sep 21, 2026

Score date Sep 22, 2026

View stock

12-month forecasts show model median estimates (P50), with changes from each forecast’s starting price. Headline scores describe dated company characteristics; they do not predict future performance.

Revolution Medicines, Inc. (RVMD)

Revolution Medicines, Inc. (RVMD) stock forecast and scoring

12M forecast summary

Stock scorecard

Company Overview

Similar Stocks

Research snapshot

Revolution Medicines, Inc. research

Revolution Medicines, Inc. (RVMD) stock forecast and scoring

12M forecast summary

Scoring · Revolution Medicines, Inc. (RVMD) stock scorecard

Scoring Breakdown

Growth

Value

Quality

Safety

Momentum

Cash Generation & Balance Strength

Stock scorecard

Company Overview